Download MendeleyThe Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.
Riggs, J.R., Nagy, M., Elsner, J., Erdman, P., Cashion, D., Robinson, D., Harris, R., Huang, D., Tehrani, L., Deyanat-Yazdi, G., Narla, R.K., Peng, X., Tran, T., Barnes, L., Miller, T., Katz, J., Tang, Y., Chen, M., Moghaddam, M.F., Bahmanyar, S., Pagarigan, B., Delker, S., LeBrun, L., Chamberlain, P.P., Calabrese, A., Canan, S.S., Leftheris, K., Zhu, D., Boylan, J.F.(2017) J Med Chem 60: 8989-9002
- PubMed: 28991472 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.7b01223
- Primary Citation Related Structures:
6B4W - PubMed Abstract:
Triple negative breast cancer (TNBC) remains a serious unmet medical need with discouragingly high relapse rates. We report here the synthesis and structure-activity relationship (SAR) of a novel series of 2,4,5-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines with potent activity against TNBC tumor cell lines. These compounds were discovered from a TNBC phenotypic screen and possess a unique dual inhibition profile targeting TTK (mitotic exit) and CLK2 (mRNA splicing). Design and optimization, driven with a TNBC tumor cell assay, identified potent and selective compounds with favorable in vitro and in vivo activity profiles and good iv PK properties. This cell-based driven SAR produced compounds with strong single agent in vivo efficacy in multiple TNBC xenograft models without significant body weight loss. These data supported the nomination of CC-671 into IND-enabling studies as a single agent TNBC therapy.
- Celgene Corporation , 10300 Campus Pointe Drive, Suite 100, San Diego, California 92121, United States.
Organizational Affiliation:
